Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05287308 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05287308 · ClinicalTrials.gov record · last posted 2022-03-31

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

Name: Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study — clinical trial record (NCT05287308)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhaseNot applicable

SponsorChinese Academy of Medical Sciences

Started2022-03

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a prospective, multi-center, real-world study designed to evaluate the efficacy and safety of albumin-bound paclitaxel versus paclitaxel or docetaxel in adjuvant treatment of breast cancer.

Amendment record 1 amendment on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended once since 2022-03-10. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details

NCT Number	NCT05287308
Lead Sponsor	Chinese Academy of Medical Sciences Collaborators: CSPC Ouyi Pharmaceutical Co., Ltd.
Conditions	Breast Cancer
Enrollment	500 participants
Start Date	2022-03
Primary Completion	2027-09 (estimated)
Study Completion	2027-09 (estimated)
Updated on ClinicalTrials.gov	2022-03-31